Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Enovis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Enovis şirketinin toplam hissedar öz sermayesi $3.3B ve toplam borcu $1.3B olup, bu da borç-öz sermaye oranını 40.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $5.4B ve $2.2B dir.

Anahtar bilgiler

40.9%

Borç/özkaynak oranı

US$1.34b

Borç

Faiz karşılama oranı	n/a
Nakit	US$35.00m
Eşitlik	US$3.29b
Toplam yükümlülükler	US$2.15b
Toplam varlıklar	US$5.44b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: C520 'nin kısa vadeli varlıkları ( $1.2B ) kısa vadeli yükümlülüklerini ( $518.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: C520 'un kısa vadeli varlıkları ( $1.2B ) uzun vadeli yükümlülüklerini ( $1.6B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: C520 'nin net borç/öz sermaye oranı ( 39.8% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: C520 'nin borç/öz sermaye oranı son 5 yılda 126.5% seviyesinden 40.9% seviyesine düştü.

Borç Kapsamı: C520 'nin borcu işletme nakit akışı ( 5.3% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: C520 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Enovis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Enovis Corporation to Report Q3, 2024 Results on Nov 06, 2024

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Continues to Redefine Revision Knee Surgery with the Addition of Emowr Revision Knee

Enovis Corporation Introduces Star Ankle, Now with E+ Polyethylene for Unmatched Durability

New minor risk - Shareholder dilution

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation to Report Q2, 2024 Results on Aug 07, 2024

Enovis Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May Be Treated with AltiVate Reverse

Enovis Corporation Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$1.32 loss per share (vs US$0.42 loss in 1Q 2023)

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Enovis Corporation, Annual General Meeting, May 20, 2024

Full year 2023 earnings released: US$0.99 loss per share (vs US$0.72 loss in FY 2022)

Enovis Corporation Provides Earnings Guidance for the Year 2024

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

No longer forecast to breakeven

Enovis Corporation Announces Leadership Transition Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$1.22 loss in 3Q 2022)

Enovis Corporation to Report Q3, 2023 Results on Nov 07, 2023

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Now 21% undervalued

Enovis Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$2.23 profit in 2Q 2022)

Enovis Corporation to Report Q2, 2023 Results on Aug 03, 2023

Enovis Corporation (NYSE:ENOV) acquired Novastep Inc. from Amplitude Surgical SA (ENXTPA:AMPLI).

Forecast breakeven date pushed back to 2024

Enovis Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.42 loss per share (vs US$0.71 loss in 1Q 2022)

Full year 2022 earnings released: US$0.71 loss per share (vs US$1.84 profit in FY 2021)

Enovis Corporation to Report Q4, 2022 Results on Feb 23, 2023

Enovis Corporation Announces the Launch of the Dynaclip Delta and Dynaclip Quattro Bone Staples

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle

Enovis Corporation Announces Introduction of DynaNail Helix

High number of new directors

Third quarter 2022 earnings released: US$1.22 loss per share (vs US$0.51 profit in 3Q 2021)

Enovis Corporation Provides Earnings Guidance for the Year 2022

Enovis Corporation to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: EPS: US$2.23 (vs US$0.59 in 2Q 2021)

Enovis Launches ARVIS®, Only Augmented Reality Surgical Guidance System Designed Specifically to Improve Both Total Hip and Knee Replacement Surgery

Enovis Corporation to Report Q2, 2022 Results on Aug 04, 2022

Enovis Corporation (NYSE:ENOV) acquired Insight Medical Systems, Inc.

Enovis Corporation Announces That Ben Berry, CFO of the Company's Business Units, Will Succeed Chris Hix as Chief Financial Officer, Effective January 1, 2023

Enovis Corporation Launches Arsenal Ankle Plating System

High number of new directors

Enovis Corporation Reaffirms Revenue Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.57 in 1Q 2021)

High number of new directors

Enovis Corporation to Report Q1, 2022 Results on May 10, 2022

Enovis Corporation Announces Board Changes

Investor sentiment deteriorated over the past week

Enovis Corporation completed the Spin-Off of ESAB Corporation (NYSE:ESAB).

Colfax Corporation Announces Board Resignations, Effective Upon the Consummation of the Separation of its Fabrication Technology Business

Executive VP of Finance & CFO recently sold €64k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Colfax Corporation Provides Earnings Guidance for the Year 2022

Colfax Corporation Announces Management Changes, Effective May 13, 2022

Third quarter 2021 earnings released: EPS US$0.17 (vs US$0.12 in 3Q 2020)

Independent Director recently sold €88k worth of stock

Co-Founder & Chairman of the Board recently bought €9.8m worth of stock

Second quarter 2021 earnings released: EPS US$0.20 (vs US$0.026 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.057 in 1Q 2020)

Colfax Corporation has completed a Follow-on Equity Offering in the amount of $644 million.

Colfax Corporation Announces Executive Changes for Two Differentiated, Independent, and Publicly-Traded Companies

Colfax Corporation Appoints Philip Okala to its Board of Directors

New 90-day high: €35.20

Full year 2020 earnings released: EPS US$0.44 (vs US$0.062 in FY 2019)

Revenue beats expectations

Colfax Corporation to Report Q4, 2020 Results on Feb 18, 2021

New 90-day high: €32.80

New 90-day high: €29.40

Colfax Corporation (NYSE:CFX) entered into an agreement to acquire certain extremity product lines from Stryker Corporation (NYSE:SYK) for $15 million.

Colfax Corporation to Report Q3, 2020 Results on Oct 29, 2020